Azenta Sells B Medical Systems for $63 Million, Secures $35M Vendor Loan
AZTA•Azenta closed the sale of its B Medical Systems unit to Thelema S.à r.l. on July 1, 2026 for $63 million in cash, with $35 million funded via a short-term secured vendor loan. The divestiture streamlines Azenta’s portfolio and boosts financial flexibility for its core life sciences operations.
1. Transaction Details
Azenta completed the sale of its B Medical Systems business to Thelema S.à r.l. on July 1, 2026, for a fixed cash price of $63 million. The deal included a short-term secured vendor loan of $35 million provided by an Azenta subsidiary to fund part of the purchase price.
2. Strategic Impact
The divestiture is part of Azenta’s strategy to simplify its portfolio and concentrate resources on its core life sciences platforms. Management expects the transaction to enhance financial flexibility and support sustainable growth in its drug development and multiomics services segments.
